Skip to content Skip to left sidebar Skip to footer


VFC/VFAAR Re-enrollment is Right Around the Corner!

VFC/VFAAR Re-enrollment is Right Around the Corner!

The Philadelphia Vaccines for Children (VFC)/ Vaccines for Adults at Risk (VFAAR) annual re-enrollment period will take place from June 1 to 30, 2022. For the third year, the enrollment will be done electronically through PhilaVax.

To get your site ready for re-enrollment, complete these steps now.

1. Update Clinic Tools
Review the information indicated for your site in the Clinic Information module. Use these job aids to guide you though making the necessary updates:

2. Make sure you have the correct level of access to PhilaVax.
The vaccine coordinator and medical director must log into the PhilaVax IIS to access, complete, and sign the electronic re-enrollment form. If you have not completed the 2022 User Confidentiality Agreement to renew your account or do not have a PhilaVax user account, use the link below to complete it now.

PhilaVax User Confidentiality Agreement
If you have trouble accessing the above link or you have a PhilaVax account and need to update your password, you can email for assistance.

Additional information and instructions will be communicated closer to the start of the re-enrollment period.
Re-enrollment is a requirement for the VFC/VFAAR programs. Failure to complete the re-enrollment form will result in un-enrollment.

Questions? Email our team at

New Vaccine Products Available through VFC

New Vaccine Products Available through VFC

10 dose boxes of pre-filled syringes of Quadracel (DTaP-IPV, NDC# 49281-0564-15, Sanofi) and of Recombivax HB (Hep B, NDC# 00006-4093-02, Merck) are now available to order through the VFC program.

If you would like to order either of these presentations for your site, please email our team at or add a comment to your next order so that we can update your site’s permissions.

National Infant Immunization Week

National Infant Immunization Week
April 24 – 30, 2022

National Infant Immunization Week (NIIW) is a yearly observance highlighting the importance of protecting children two years and younger from vaccine-preventable diseases (VPDs). This year, in particular, it’s critical to ensure that families stay on track for children’s routine checkups and recommended vaccinations following disruptions from COVID-19.

Research has consistently shown that healthcare professionals are the most trusted and influential source of vaccine information for parents. All staff in healthcare practices, including non-clinical staff, play important roles during NIIW.

To highlight childhood immunizations this NIIW:

Additional resources are available from the CDC:

Sanofi Discontinuing Menactra

Sanofi Discontinuing Menactra

In mid-2022, Sanofi will only offer MenQuadfi as their meningococcal ACYW conjugate (MCV4) vaccine. They will discontinue the distribution of Menactra in the US.

Sites currently using Menactra, need to transition to one of the other MCV4 products available: Menveo from GSK or MenQuadfi from Sanofi. The exact timing of the transition will be determined by usage over the coming months and inventory on hand in the CDC depots to minimize vaccine wastage.

To prepare for the transition, complete the below survey to let us know which MCV4 vaccine your site plans to order moving forward.

Complete the survey.

Adolescent Immunization Action Week

Adolescent Immunization Action Week

Adolescent Immunization Action Week gears up to get adolescents up to date on immunizations.

April 4 to April 8 is the first annual National Adolescent Immunization Action Week. Unity® Consortium launched this initiative to bring attention to the importance of adolescent immunization and to urge health care providers and parents to get adolescents up to date on recommended vaccines.

Research has consistently shown that healthcare professionals are the most trusted and influential source of vaccine information for parents.

Visit Unity’s AIAW campaign page for social media-ready materials and graphics you can use to communicate and draw attention to the importance of taking action now to improve adolescent immunization coverage.

Here are ideas to remind, recall, and schedule immunizations:

Together we can help mitigate the impact of COVID-19 on adolescent immunization rates and help to prevent future outbreaks of vaccine-preventable diseases.

PhilaVax IIS Closed to VFC/VFAAR Orders from 3/31 through 4/4

PhilaVax IIS Closed to VFC/VFAAR Orders from 3/31 through 4/4

PhilaVax will be temporarily closed to new VFC/VFAAR orders from 12PM on Thursday, March 31 until 9AM on Monday, April 4 while the vaccine prices are updated for 2022.

During this time, any orders entered into PhilaVax IIS will be deleted from the system and not processed.

If you need to a place order, submit it before 12 PM on Thursday, March 31.

Normal order processing and shipping will resume at 9 AM on Monday, April 4.

Have questions about VFC/VFAAR ordering or shipping around the temporary closure? Our team is here to help!

Email or
Or call 215-685-6728 or 215-685-6667.

Thank you for keeping Philadelphia healthy!

New VFC/VFAAR Vaccine Packaging

New VFC/VFAAR Vaccine Packaging

Follow these instructions to return the new eco-friendly vaccine packaging to McKesson and Merck.

Refrigerated Vaccines

McKesson is using the EcoFlex96 shippers to ship refrigerated VFC and VFAAR vaccines. These shippers must be returned to avoid interruption of your vaccine shipments.

Use these instructions to return EcoFlex96 shippers.

The return shipping label should be attached to the inner flap on the box. If no return label was provided, please contact Christine Wilson ( or Charma Miller ( for assistance in obtaining the return label.

If UPS regularly delivers to your site, the empty shipper(s) can be left in the usual location for pick up and return.

To schedule a pick up, call (774)-233-7106 or email, provide the return tracking number and the address for pick up, and a pick up will be scheduled for you.

Frozen Vaccines

Merck is transitioning to reusable shipping containers (pictured below) to ship frozen VFC and VFAAR vaccines. These shippers must be returned to avoid interruption of your vaccine shipments.

For detailed instructions and additional information, please use this link to view a quick video:

Each shipper will be preaddressed to AeroSafe.

Please contact Christine Wilson ( or Charma Miller ( with any questions about the process.

Recommend HPV Vaccine at Every Visit!

Recommend HPV Vaccine at Every Visit!

During the first year of the COVID-19 pandemic, there was a decrease in HPV doses administered in the United States.

Here in Philadelphia, there was a 29% decrease in the total number of HPV doses administered in 2020 compared to 2019. This decrease affected every eligible age group:

  • 9-13 year olds: HPV doses administered decreased by 17.5% from 2019 to 2020.
  • 13-17 year olds: HPV doses administered decreased by 41.7% from 2019 to 2020.
  • 18-26 year olds: HPV doses administered decreased by 53.7% from 2019 to 2020.

March 4 is International HPV Awareness Day!

To help bring HPV vaccination rates back to pre-pandemic levels, recommend HPV vaccine at every visit for 9-26 year olds who have not begun or completed their series. 

Register for this CME webinar on March 2 from 1-2pm EST! Dr. Danielle Casher (Attending Physician, Children’s Hospital of Philadelphia) will join cancer survivor Megan Lesar to discuss improving HPV vaccine rates in Pennsylvania.

On March 4, watch and share this video from the Association of Immunization Managers (AIM) to promote timely, complete HPV vaccination.

Steps to Recommend HPV Vaccine to Hesitant Parents


  • Your child is __ years old.
  • Today, they are eligible to receive Tdap, HPV, and MCV vaccine.
  • We will make sure they get all these shots to keep them safe and healthy.

If parent hesitates:

Connect and Counsel:

  • What’s your main concern?
  • Counsel using a research-tested method (ex.”Over 30,000 Americans get cancer from HPV every year. Most could be prevented with the HPV vaccine.”)

If parent declines:

Try Again

  • Almost 70% of parents who initially declined later agree to HPV vaccine or plan to vaccinate soon.




Have questions? Reach out to our team at Thank you for all that you do to keep Philadelphia safe and healthy!

Younger Pediatric COVID-19 Vaccine Coming Soon!

Younger Pediatric COVID-19 Vaccine Coming Soon!

The COVID-19 vaccine for children 6 months through 4 years of age is expected to be approved as early as the end of February.

We need your help as trusted providers to ensure these children have access to vaccination.

Here’s why:

  • To ensure access. Children under 3 cannot be vaccinated in pharmacies and will have limited options of where to seek vaccination.
  • To meet a real need. Nationally, 70% of parents with kids in this age group are ready or close to ready to having their children vaccinated against COVID-19.
  • Parents trust you. The vast majority of these parents would prefer to take their children to their regular provider to be vaccinated.

Your practice is key to vaccinating these younger children.

Click below to watch a video statement from Philadelphia Health Commissioner, Cheryl Bettigole, on the importance of this initiative.

What Can Your Practice Do to Be Ready?

Enroll: If you have not already enrolled, enroll now in the COVID-19 vaccine distribution program.

Spread the word: Let your families know you will be offering COVID-19 vaccine as soon as it becomes available. Order COVID-19 outreach materials (stickers, buttons, posters) at no cost to your practice.

Order: Order vaccine early and often.

Thank you for keeping Philadelphia safe and healthy. If you have any questions, please email

2022-2023 Flu Season Changes and Survey

2022-2023 Flu Season Changes and Survey

Flu Season Planning Survey

Please complete our 2022-23 Flu Season Planning Survey by Friday, 1/21. Your responses are key in our planning for the next flu season.

Take the Survey

Changes for the 2022-2023 Flu Season

The FDA recently approved the expansion of the age range for a cell based manufactured vaccine, Flucelvax. Under this expansion Flucelvax can be administered to individuals 6 months of age and older.

The flu viruses used in the cell-based vaccines are grown in cultured cells of mammalian origin instead of in hens’ eggs. Most inactivated flu vaccines are produced by growing flu viruses in eggs.

Cell-based flu vaccine production does not use flu viruses grown in eggs and, therefore, is not dependent on the supply of eggs. In addition, cell-based flu vaccines have the potential to offer better protection than traditional, egg-based flu vaccines.

The viruses used to make cell-based vaccines may be more similar to circulating “wild” flu viruses than the viruses used to make egg-based vaccines. Growing flu viruses in eggs can introduce changes (called egg-adapted changes) that can cause differences between the viruses in the vaccine and the ones that are circulating. These changes may have important implications for the body’s immune response to vaccination. For example, egg-adapted changes could cause the body’s immune system to produce antibodies that are less effective at preventing disease caused by the specific flu viruses in circulation.

You can find more information about the types of flu vaccines approved for use in the US on the CDC website here:
Flu Vaccines:
Recombinant Flu Vaccines:
Cell-Based Vaccines:
Flucelax Package Insert: